CFL1P4: A Potential Drug Target and Biomarker (G645980)

Target Name: CFL1P4

NCBI ID: G645980

CFL1P4

Other Name(s): CFLP4 | CFLL4 | cofilin 1 pseudogene 4 | Cofilin 1 (non-muscle) pseudogene 4

CFL1P4: A Potential Drug Target and Biomarker

Introduction

CFL1P4 (CFLP4) is a protein that is expressed in various tissues of the human body, including the brain, heart, liver, and pancreas. It is a member of the Cytoskeleton-associated protein family, which is known for their role in regulating cell signaling and cytoskeletal organization.

Recent studies have identified CFLP4 as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This has led to increased interest in the research of CFLP4 as a drug development target and its potential as a biomarker for disease diagnosis and treatment.

Potential Drug Target

CFLP4 has been shown to play a role in a variety of cellular processes that are important for human health, including the development and progression of cancer, neurodegenerative diseases, and autoimmune disorders. Its role in these processes makes it an attractive target for drug development.

One of the key features of CFLP4 is its ability to interact with various signaling pathways, including the TGF-尾 pathway. This pathway is involved in the development and maintenance of cellular organization and has been implicated in a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

CFLP4 has been shown to play a role in the regulation of TGF-尾 signaling by inhibiting the activity of the transcription factor, SMAD. This has led to the conclusion that CFLP4 may be a useful target for drugs that are designed to inhibit TGF-尾 signaling and prevent the development and progression of cancer, neurodegenerative diseases, and autoimmune disorders.

Biomarker

CFLP4 has also been shown to be a potential biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its ability to interact with various signaling pathways and its involvement in regulation in the cellular organization make it an attractive candidate for use as a biomarker.

One of the key advantages of CFLP4 as a biomarker is its ability to be expressed in a variety of tissues and cells, including cancer cells, neurodegenerative disease cells, and immune cells. This allows for its use as a biomarker to be detected in a variety of biological samples, including urine, blood, saliva, and tissue samples.

In addition, CFLP4 has been shown to be expressed in various disease-associated proteins, including PDGF-灏?, TGF-浼?, and NF-kappa-B. This suggests that it may be involved in the regulation of these proteins and their role in the development and progression of various diseases.

Conclusion

CFLP4 is a protein that has been shown to play a role in a variety of cellular processes that are important for human health. Its potential as a drug target and biomarker has led to increased interest in its research and development as a potential therapeutic agent.

While further research is needed to fully understand the role of CFLP4 in disease development and progression, its potential as a drug target and biomarker is a promising area of 閳ュ??濯爐udy that may have significant implications for the treatment of a variety of diseases.

Protein Name: Cofilin 1 Pseudogene 4

The "CFL1P4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CFL1P4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets